Sana Biotechnology boosts IPO range, looks to raise $517 million

GeekWire

Sana Biotechnology — the Seattle upstart that’s looking to treat a variety of diseases through gene therapy and cell engineering — is generating buzz on Wall Street. That would net the biotechnology company $517 million if it sold at the midpoint of that range.

Sana Biotechnology files to go public, looks to cure disease by modifying genes in the body

GeekWire

Less than three years after it was founded and with no revenue on the books, Sana Biotechnology has f iled to go public. And like many biotechnology companies it is losing money. Startups Biotech IPOs Sana BiotechnologySana CEO Steve Harr (Sana photo).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jeff Bezos-backed startup Nautilus Biotechnology set to go public via SPAC at $900M valuation

GeekWire

Nautilus Biotechnology co-founders Sujal Patel (left) and Parag Mallick. Nautilus Biotechnology , a Seattle-based biotech startup led by Isilon co-founder Sujal Patel , is the latest company to go public using a special purpose acquisition company, or SPAC.

Adaptive Biotechnologies and Microsoft team up to track coronavirus-fighting cells

GeekWire

Seattle-based Adaptive Biotechnologies and Microsoft have launched an open-access database called ImmuneCODE to catalog the many ways in which our immune systems fight off a coronavirus infection. Check out this GeekWire Health Tech Podcast for more about Adaptive Biotechnologies’ collaboration with Microsoft on COVID-19 studies. Health/Life Sciences Science Adaptive Biotechnologies coronavirus immune system immune therapy ImmuneCODE Microsoft Microsoft Health

Adaptive Biotechnologies posts $26.3M in Q3 revenue, inks partnership with GlaxoSmithKline

GeekWire

Adaptive Biotechnologies CEO Chad Robins. Adaptive Biotechnologies beat expectations for its fiscal third quarter as the Seattle company continues to use its immune medicine platform in the fight against COVID-19. Tech Adaptive Biotechnologies

Adaptive Biotechnologies will sell 8M shares to accelerate drug development

GeekWire

Adaptive Biotechnologies announced Tuesday that it will sell 8 million shares of its common stock — 6 million of its own, and 2 million from an investor — to help accelerate the company’s work. Health/Life Sciences Adaptive BiotechnologiesThe money will go toward investments in its TCR-Antigen Map activities, marketing activities associated with immunoSEQ Dx clinical products and services, and continued R&D for drug discovery initiatives.

Tech Moves: Accolade’s new board member; Adaptive Biotechnologies names a COO; and more

GeekWire

Adaptive Biotechnologies). Adaptive Biotechnologies has promoted one exec, while another is departing next month. Adaptive Biotechnologies’ EVP of Operations and Management Nancy Hill will depart the company in March. Cindy Kent. Accolade Photo).

Promising Gene Therapy Trials Suspended Over Potential Cancer Risk

GizModo VR

therapy cancer gene therapy myelodysplastic syndrome thalassemia health medical pharma sickle cell disease life sciences biotechnology molecular biology biology branches of biology gene delivery bluebird

Common DNA Testing Method Has High False-Positive Rate for Rare Mutations, Study Finds

GizModo VR

dna biotechnology molecular biology snp array biology genetics genomics bioinformatics health medical pharma single nucleotide polymorphism genetic testing whole genome sequencing branches of biology

Don't Share Your Vaccine Card on Social Media

GizModo VR

entertainment_culture human interest technology_internet biotechnology vaccination articles life sciences biologyAs more people receive the vaccine, we’re also seeing more of them post photos of their vaccine cards to social media.

Media 83

Living algae facades cover buildings, sucking in CO2 and sun to produce renewable energy

Mashable VR

More about Design , Renewable Energy , Facade , Algae , and Biotechnology. Design Renewable Energy Facade Algae Biotechnology

Testing a new COVID-19 test: How T-cells beat antibodies in helping to detect past infections

GeekWire

This was a first-of-its kind diagnostic tool from Seattle-based Adaptive Biotechnologies , a company that develops technology to sequence the human immune system for the diagnosis and treatment of disease. Adaptive Biotechnologies Photo).

Tech Moves: Amazon’s director of Alexa Trust; BECU adds CIO; Lockstep, Fabric exit stealth mode

GeekWire

Andris Zoltners stepped down from the board of publicly traded Seattle-based Adaptive Biotechnologies after 11 years. . Nautilus Biotechnology Photo). Anne Toth. Amazon Photo).

Adaptive Biotech pushes ahead with new Seattle HQ, showing strength of life sciences industry

GeekWire

Chad Robins, CEO of Adaptive Biotechnologies, speaks at the site of the company’s future corporate headquarters in Seattle, standing in front of the final piece of structural steel before it’s put into place. Stephen Brashear/AP Images for Adaptive Biotechnologies).

Adaptive Biotech revenue up 25%; company launches T-cell test for past COVID-19 infections

GeekWire

Seattle-based Adaptive Biotechnologies, which develops technology to sequence the human immune system to diagnose and treat disease, posted revenue of $30.2 Tech Adaptive Biotechnologies chad robins COVID-19 T-cells

.Net 78

Adaptive plans fall launch of T-cell test for past COVID-19 detection, as alternative to antibody tests

GeekWire

Adaptive Biotechnologies says it’s proceeding with plans to launch a new type of test to determine if someone was previously infected with SARS-CoV-2, the virus that causes COVID-19, after a study added to the evidence that its approach is more accurate than currently available antibody tests.

GeekWire Podcast: What Seattle’s billion-dollar startups say about the region’s tech industry

GeekWire

Podcasts Auth0 convoy Flying Fish Partners Heather Redman Icertis OfferUp outreach Qumulo Remitly Sana Biotechnology Tanium ZenotiSeattle’s billion-dollar tech club, startups with valuations of more than $1 billion. GeekWire Graphic).

Seattle area boasts 10 fast-growing unicorns: Can you name the billion dollar startups?

GeekWire

Sana Biotechnology. Startups Auth0 convoy Icertis OfferUp outreach Qumulo Remitly Sana Biotechnology Tanium unicorns ZenotiThere are 10 unicorn startups in the Seattle area valued at $1 billion or more. Shutterstock Photo).

Researcher with Seattle ties awarded $4.2M to develop DNA vaccine against COVID-19

GeekWire

OncoSenX is the spinoff of a third company, Seattle-based Oisin Biotechnologies. Tech Biotech Biotechnology COVID-19 COVID-19 vaccine oncosenxJohn Lewis, co-founder and chief scientific officer at Seattle’s OncoSenX, and co-founder and CEO of Entos Pharmaceuticals in Edmonton, Alberta. LinkedIn Photo). A researcher with ties to Seattle-based biotech company OncoSenX has received a $4.2

Tech Moves: Microsoft’s Brad Anderson jumps to Qualtrics in wave of pre-IPO hires; Elena Donio joins Databricks board; Hiya, Esper add startup vets

GeekWire

Other recent Tech Moves from across the Pacific Northwest: Seattle-based AVM Biotechnology appointed Manon Cox as its new CEO and Gary Grohmann as chief regulatory officer. Longtime Microsoft executive Brad Anderson is moving back to his hometown in Utah as part of his new role at Qualtrics.

SAP 84

This 35-year-old female CEO is about to crack the glass ceiling, shattering a dismal IPO track record

GeekWire

The 35-year-old co-founder and CEO of Seattle biotechnology company Athira Pharma would be the first woman to guide a company to an initial public offering in Washington state in more than two decades. ” Startups Athira Pharma Biotechnology IPOs leen kawas

Industry slowdown hits Adaptive Biotech’s bottom line as COVID immune initiatives show progress

GeekWire

Chad Robins, left, is co-founder and CEO of Adaptive Biotechnologies, which he co-founded with his brother, Harlan Robins, right, a theoretical physicist turned computational biologist who is the company’s chief scientific officer. Adaptive Biotechnologies Photo).

.Net 68

Merck’s multi-billion dollar bet on Seattle Genetics sparks hope for breast cancer treatments

GeekWire

based biotechnology company struck a deal with Merck in which the pharmaceutical powerhouse will provide a $600 million upfront payment and make a $1 billion equity investment to continue development of treatments for breast cancer. Health/Life Sciences Biotechnology Seattle Genetics

Adaptive Biotech revenue rises 65% to $21M, loss widens amid big COVID-19 immune partnerships

GeekWire

Adaptive Biotechnologies CEO Chad Robins. Adaptive Biotechnologies, which is working with Microsoft and Amgen to fight COVID-19 using its technology for sequencing the human immune system, reported a 65% increase in first quarter revenue , to nearly $21 million. Health/Life Sciences Adaptive Biotechnologies Amgen chad robinsGeekWire File Photo).

Inside the quest for a new COVID-19 test: Microsoft, Adaptive Biotech and the hidden power of immunity

GeekWire

Two companies in the Seattle region, Microsoft and Adaptive Biotechnologies, are on a quest to create a better diagnostic test. Health Tech Podcast Adaptive Biotechnologies chad robins COVID-19 Microsoft Peter LeeAdaptive Biotech CEO Chad Robins (left) and Peter Lee, Microsoft corporate vice president of AI and Research, on a video call this week for GeekWire’s Health Tech Podcast.

Study 73

Secretive Seattle biotech company raises more than $700M to develop new ways to modify genes

GeekWire

Sana Biotechnology today formally announced that it has raised more than $700 million in venture funding — one of the largest venture financing deals in the life sciences industry and one of the biggest rounds on record in Seattle. Health/Life Sciences Biotechnology Funding fundings sana Venture capitalSteve Harr (Sana Photo).

GeekWire Podcast: What pandemic? Tech funding stays strong; Accolade’s IPO; Future of sports

GeekWire

Health/Life Sciences Podcasts Startups Accolade Funding GeekWire Events IPO Sana BiotechnologyHere’s what we’re talking about on the GeekWire Podcast this week. Despite the pandemic, funding for Pacific Northwest tech startups remains robust in the first half of 2020. In fact, funding is ahead of last year. What gives? We consider whether COVID-19 is accelerating some companies into the new economy of remote working, online shopping and heightened awareness of health and life sciences.

Harry Potter's invisibility cloak is almost a reality, but only for likely military use

Mashable VR

Canadian camouflage company Hyperstealth Biotechnology is working on a 'cloak' that can render some objects nearly invisible from certain angles. The cloak uses a technology called Quantum Stealth to bend light around people or objects.

How SPACs are changing the IPO game: Equity ownership of founders a big consideration

GeekWire

A few weeks ago, a longtime GeekWire reader sent a note expressing shock that Sana Biotechnology co-founder and CEO Steve Harr only owned 4.9% For example, take Seattle-based Nautilus Biotechnology. Adaptive Biotechnologies CEO Chad Robins: 6.3%

Well-funded stealthy biotech startup Nautilus hires former Smartsheet, Isilon, GenapSys execs

GeekWire

Nautilus Biotechnology Photos). Sujal Patel is getting the band back together at his secretive new biotech startup Nautilus Biotechnology. Nautilus Biotechnology co-founders Sujal Patel and Parag Mallick.

Scientists find more potential ingredients for ‘antibody cocktail’ that fights COVID-19

GeekWire

UW’s David Veesler and Vir Biotechnology’s Katja Fink are the senior authors of the study published online today by the journal Science , which highlights two monoclonal antibodies known as S2E12 and S2M11. A drug that takes advantage of S309’s effect is already being tested in a phase 2/3 clinical trial launched by GlaxoSmithKline and Vir Biotechnology.

Seattle biotech Athira Pharma sets terms for IPO, aims to raise up to $170M

GeekWire

Formerly known as M3 Biotechnology, the company is led by Leen Kawas, a 35-year-old CEO who would be the first woman to guide a company to an initial public offering in Washington state in more than two decades.

Seattle biotech firm Umoja Biopharma raises $53M as it tackles unique approach to immunotherapy

GeekWire

Others include Sana Biotechnology, Chinook Therapeutics, Kineta, Alpine Immune Sciences, Adaptive Biotechnologies, and more, in addition to work being done at Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Benaroya Research Institute, and others.

Seattle biotech startup OncoSenX raising more cash for cancer-fighting therapies

GeekWire

OncoSenX is a spinout out of Oisin Biotechnologies, a 5-year-old Seattle company also led by Scholz, a veteran biotech entrepreneur. Biotech startup OncoSenX is raising more cash to help support its pipeline of therapeutics that aim to kill cancer cells based on their genetics. Its technology targets solid tumors based on a patented lipid nanoparticle gene delivery system and a highly targeted DNA payload.

Seattle biotech startup led by Fred Hutch, Adaptive vets raises $16M for rapid drug development tech

GeekWire

Lumen is led by Finrow, a former senior vice president at Adaptive Biotechnologies, and Chief Science Officer Jim Roberts , the former head of basic sciences at the Fred Hutchinson Cancer Research Institute. Lumen Chief Science Officer Jim Roberts (left) and CEO Brian Finrow. Lumen Photo).

Athira Pharma prices IPO at $17/share, will raise $204M in third Washington state IPO of 2020

GeekWire

Formerly known as M3 Biotechnology, the company is led by Dr. Leen Kawas , a 35-year-old CEO who will be the first woman to guide a company to an initial public offering in Washington state in more than two decades. The Athira team. Athira Photo).

Fred Hutch, Univ. of Washington biotech spinout Ensoma launches with $70M in funding

GeekWire

Spinout success: Other Fred Hutch spinouts include Juno Therapeutics and Adaptive Biotechnologies, while University of Washington research led to the launch of Icosavax, Neoleukin Therapeutics, Universal Cells, Cyrus Biotechnology and others.

Baby Yoda’s real name and Bill Gates’ podcast pal: Test your geek smarts with our year-end news quiz

GeekWire

In June, Seattle biotechnology upstart Sana Biotechnology revealed that it had raised more than $700 million in venture funding. Which of these Washington state companies did NOT go public in 2020: Accolade, Adaptive Biotechnologies, Athira Pharma, Silverback Therapeutics?

A SPAC called FLAC? Seattle venture capital firm to launch $100 million ‘blank check’ company

GeekWire

Frazier Healthcare Partners — which has invested in biotechnology companies since 1991 — filed with the Securities and Exchange Commission to raise $100 million for a special purpose acquisition corporation, also known as a SPAC. James Topper serves as CEO Of FLAC. Photo via Frazier).

Notch Therapeutics raises $85M for cancer treatments and plans to open Seattle location

GeekWire

Local immunotherapy biotech companies include Umoja Biopharma, Sana Biotechnology, Chinook Therapeutics, Kineta, Alpine Immune Sciences, Adaptive Biotechnologies, and others.

Sana CEO reveals details about stealthy gene therapy startup that has raised more than $700M

GeekWire

Luke Timmerman interviews Sana Biotechnology CEO Steve Harr at the GeekWire Summit this week. Harr spoke with biotechnology journalist Luke Timmerman, founder of The Timmerman Report , this week at the GeekWire Summit. Luke Timmerman (left) interviews Sana Biotechnology CEO Steve Harr.

Tech stocks soar in 2020 amid pandemic as Seattle-area companies see valuations spike

GeekWire

Biotechnology companies had a good year. Adaptive Biotechnologies, CTI Biopharma, Aptevo Therapeutics and Silverback Therapeutics posted gains of 99% or more. Adaptive Biotechnologies.

Arizona State University Adopts Hortonworks Data Platform to Shed Light on the Genetic Links to Cancer

CTOvision

ASU researcher improves crop performance with new biotechnology (eurekalert.org). Katie Kennedy. Recently announced, Arizona State University (ASU) is using Hortonworks Data Platform (HDP™) to further cancer research. With HDP, ASU researchers have the tools they need to store, process, and query more data at a faster pace, allowing researchers to ask better questions and uncover new links between genetics and cancer.